Adaptive multi-drug treatment of evolving cancers (AMTEC): A phase II, open-label, study of Olaparib in combination with either Durvalumab, Selumetinib or Capivasertib, or Ceralasertib monotherapy in patients with metastatic TNBC
Capivasertib;Ceralasertib;Durvalumab;Olaparib;Selumetinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Adaptive multi-drug treatment of evolving cancers (AMTEC): A phase II, open-label, study of Olaparib in combination with either Durvalumab, Selumetinib or Capivasertib, or Ceralasertib monotherapy in patients with metastatic TNBC ### Output: Capivasertib;Ceralasertib;Durvalumab;Olaparib;Selumetinib